3 Stocks Dragging The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 37 points (-0.2%) at 16,809 as of Friday, June 27, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,843 issues advancing vs. 1,114 declining with 177 unchanged.

The Health Care sector currently sits up 0.2% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include Alexion Pharmaceuticals ( ALXN), down 1.5%, WellPoint ( WLP), down 0.9%, UnitedHealth Group ( UNH), down 0.7%, Aetna ( AET), down 0.7% and Vertex Pharmaceuticals ( VRTX), down 0.7%. Top gainers within the sector include Taro Pharmaceutical Industries ( TARO), up 13.9%, Intuitive Surgical ( ISRG), up 2.7%, Fresenius Medical Care AG & Co. KGaA ( FMS), up 1.6%, Endo International ( ENDP), up 1.3% and Valeant Pharmaceuticals International ( VRX), up 1.3%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Regeneron Pharmaceuticals is down $7.72 (-2.8%) to $272.08 on heavy volume. Thus far, 854,533 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 863,400 shares. The stock has ranged in price between $269.50-$281.95 after having opened the day at $280.00 as compared to the previous trading day's close of $279.80.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $27.8 billion and is part of the drugs industry. Shares are up 1.7% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and weak operating cash flow. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round